Published in BMC Infect Dis on December 28, 2011
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology (2014) 2.18
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial. Clin Infect Dis (2016) 1.44
Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One (2014) 1.21
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12
Controversies in HIV-associated neurocognitive disorders. Lancet Neurol (2014) 1.07
Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med (2011) 1.05
A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One (2013) 0.97
Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev (2013) 0.95
The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci (2013) 0.95
A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS (2015) 0.90
Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis (2012) 0.89
Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis (2014) 0.89
Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.87
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. PLoS One (2014) 0.86
Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder. J Acquir Immune Defic Syndr (2014) 0.85
Screening for Neurocognitive Impairment in HIV Individuals: The Utility of the Montreal Cognitive Assessment Test. J AIDS Clin Res (2012) 0.83
Association between brain volumes and HAND in cART-naïve HIV+ individuals from Thailand. J Neurovirol (2015) 0.81
HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study. PLoS One (2014) 0.81
The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. CNS Drugs (2016) 0.80
Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Curr Opin HIV AIDS (2014) 0.79
Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One (2016) 0.77
Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients. J Neurovirol (2015) 0.76
Health-Related Decision-Making in HIV Disease. J Clin Psychol Med Settings (2016) 0.76
A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis (2016) 0.76
Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy. J Neuroinflammation (2016) 0.76
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. J Neurovirol (2015) 0.75
The Role of HIV Infection in Neurologic Injury. Brain Sci (2017) 0.75
Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic. PLoS One (2016) 0.75
Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis (2016) 0.75
Predictors and impact of self-reported suboptimal effort on estimates of prevalence of HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2017) 0.75
Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
Prevalence and Correlates of HIV-Associated Neurocognitive Disorders (HAND) in Northwestern Nigeria. Neurol Res Int (2015) 0.75
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses (2008) 1.84
Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol (2011) 1.51
Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis (2011) 1.37
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol (2010) 1.07
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand (2004) 2.26
Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study. BMC Med (2013) 2.20
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 2.17
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 1.92
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion (2008) 1.73
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. Obstet Gynecol (2005) 1.70
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Approach to managing undiagnosed chest pain: could gastroesophageal reflux disease be the cause? Can Fam Physician (2007) 1.61
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Retracted Folic acid supplementation, dietary folate intake during pregnancy and risk for spontaneous preterm delivery: a prospective observational cohort study. BMC Pregnancy Childbirth (2013) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer (2011) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol (2002) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Persisting hypoxaemia is an insufficient measure of adverse lung function in very immature infants. Arch Dis Child Fetal Neonatal Ed (2013) 1.40
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
The very obese woman and the very old woman: tension-free vaginal tape for the treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.38
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst (2002) 1.26
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol (2004) 1.20
Pubertal timing is an independent predictor of central adiposity in young adult males: the Gothenburg osteoporosis and obesity determinants study. Diabetes (2006) 1.19
Mice chronically fed high-fat diet have increased mortality and disturbed immune response in sepsis. PLoS One (2009) 1.18
Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke (2006) 1.17
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis (2004) 1.14
Low-dose aspirin in a short regimen as standard treatment in in vitro fertilization: a randomized, prospective study. Fertil Steril (2004) 1.10
Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet (2010) 1.10
Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol (2006) 1.09
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res (2003) 1.07
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest (2012) 1.05
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. Arch Gen Psychiatry (2003) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab (2006) 1.03
Airborne chemistry: acoustic levitation in chemical analysis. Anal Bioanal Chem (2004) 1.02
Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril (2008) 1.02
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther (2005) 1.02
Laser techniques in acoustically levitated micro droplets. Lab Chip (2004) 1.01
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev (2010) 1.00
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol (2012) 0.99
Frequency of de novo urgency in 463 women who had undergone the tension-free vaginal tape (TVT) procedure for genuine stress urinary incontinence--a long-term follow-up. Eur J Obstet Gynecol Reprod Biol (2006) 0.99
T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J Acquir Immune Defic Syndr (2005) 0.99
Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One (2013) 0.98
Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism (2008) 0.98
Low-oxygen compared with high-oxygen atmosphere in blastocyst culture, a prospective randomized study. Fertil Steril (2008) 0.98
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (2014) 0.98
Pubertal timing predicts previous fractures and BMD in young adult men: the GOOD study. J Bone Miner Res (2006) 0.97
BMI changes during childhood and adolescence as predictors of amount of adult subcutaneous and visceral adipose tissue in men: the GOOD Study. Diabetes (2009) 0.97
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96
Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects. PLoS One (2013) 0.96
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95
Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? J Psychiatry Neurosci (2012) 0.94
Association of pro-ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass. Alcohol Clin Exp Res (2008) 0.94
Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya. PLoS One (2012) 0.93
Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3. Genes Chromosomes Cancer (2007) 0.93
A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease. PLoS One (2013) 0.93
Fibrinolytic gene polymorphism and ischemic stroke. Stroke (2005) 0.92
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial. Scand J Infect Dis (2013) 0.92
Meta and pooled analysis of European coeliac disease data. Eur J Hum Genet (2003) 0.91
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis (2011) 0.91
Influence of androgen receptor repeat polymorphisms on personality traits in men. J Psychiatry Neurosci (2009) 0.90
Airborne chemistry coupled to Raman spectroscopy. Anal Chem (2003) 0.90
Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One (2012) 0.90
Association of nAChR gene haplotypes with heavy alcohol use and body mass. Brain Res (2009) 0.89
Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. Int J Oncol (2004) 0.89
Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS (2005) 0.89
Sex steroid-related genes and male-to-female transsexualism. Psychoneuroendocrinology (2005) 0.89
Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials (2007) 0.89
The risk of celiac disease in 107 families with at least two affected siblings. J Pediatr Gastroenterol Nutr (2004) 0.89
Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet (2005) 0.89
CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain (2004) 0.89
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Use of nanoparticles in capillary and microchip electrochromatography. J Chromatogr A (2007) 0.88
Analysis of chromosome 5q31-32 and psoriasis: confirmation of a susceptibility locus but no association with SNPs within SLC22A4 and SLC22A5. J Invest Dermatol (2006) 0.88